The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
To think I was apologising 6 weeks ago for selling 50,000 from my holding at 24.1p. I just bought them back this morning at 21.8p. We had some useful advice from Hydrogen back then that it was a good time to sell with a fund looking to buy and build a stake.
I remain a long term holder of MTR even if it does try my patience. I will continue to sell / buy on the peaks and troughs as we go - and I'll stop apologising about it now...
Fierce1: yes the copper price is rising, Sandfire share price rising, drilling continues in Botswana, big share purchases recently etc etc. All the conditions in place which I hoped would drive the share price well above 30p.
But we are still stuck at around 25p. Maybe we've all got into a "groupthink" mode on this BB to convince ourselves that the future is bright for MTR. Maybe it's time to ask the question "is this as good as it's going to get?"
Arix Bioscience (LON:ARIX)said its portfolio company, Amplyx Pharmaceuticals, has received positive data from its Phase 2 clinical trial of its antifungal agent, fosmanogepix.
The trial, which was set up to evaluate the safety and efficacy of its novel, broad-spectrum antifungal agent fosmanogepix, as a first-line treatment for patients with invasive fungal infections caused by the fungus strain Candida. Fosmanogepix, successfully met its primary efficacy endpoint, demonstrating a treatment success rate of 80%.
Invasive fungal infections represent a serious threat to millions of patients globally, resulting in more than 1.5 million deaths annually and mortality rates ranging from 15% to 65%.
These infections continue to be a global health issue, especially for critically ill patients in hospitals and patients with compromised immune systems, including cancer and transplant patients.
During the trial, patients were treated with fosmanogepix for up to 14 days: 1,000 mg intravenously twice a day for one day, then 600 mg intravenously once daily for at least two days, followed by either 600 mg intravenously once daily or 700 mg orally once daily.?
The clinical-stage biopharmaceutical firm said fosmanogepix was well tolerated by patients during the trial with no treatment-related serious adverse events or discontinuations.
Shares in Arix Bioscience have traded well over the past three months from lows of 81p in May 2020 to 86.5p on Monday afternoon trading following this announcement.
In addition, fosmanogepix demonstrated potent in vitro activity against all Candida isolates obtained from patients in this study, including isolates resistant to other antifungal agents.
Fosmanogepix has received Fast Track and Orphan Drug designations from the US FDA for seven separate indications and is also designated as a Qualified Infectious Disease Product for the treatment of four indications.
“We are very encouraged that fosmanogepix demonstrated a high rate of treatment success, including activity against resistant pathogens, and was well tolerated in patients with invasive Candida infections,” said Michael R. Hodges, Chief Medical Officer of Amplyx.
He added, “The positive efficacy and safety data from this trial continue to highlight the promise of fosmanogepix as a novel and differentiated treatment option for patients who develop life-threatening invasive fungal infections.?
We look forward to advancing the fosmanogepix program in invasive candidiasis towards registration, while continuing our proof-of-concept clinical trials in other invasive fungal infections, including invasive aspergillosis.”
****************************/articles/arix-bioscience-notes-positive-clinical-data-from-amplyx-pharmaceuticals--5235293/
Off topic so apologies but this may be of interest to Tigers as it's a copper / gold project in Namibia. May be worth a look and I'd be interested to hear any views on it..check out Bezant Resources BZT
The ongoing technical review has identified the project as a high-grade copper-gold volcanic massive sulphide (VMS) project located in Namibia. The project area contains a combined Mineral Resource of 10.2Mt at 1.9% copper and 0.3g/t of gold at a 0.7% copper cut-off, reported in accordance with the JORC Code (2012).
****************************/articles/bezant-resources-says-gold-grade-at-hope-project-significantly-underestimated--fd2a3f5/
Not much life in the share price at the moment - flat as a pancake :-)
Steady buying today ahead of the market update. I've added to my holding this morning. Anticipating some solid results and a further pay down of debt. So that they can pay us a big fat dividend for our patience when divis resume...
I've sold a few. Not out of any concern with MTR's prospects - just rebalancing my portfolio and banking some profit as I am heavily overweight on MTR. Still holding a truck load of these shares so let's hope the rise continues. GLA.
Encouraging signs and I'm finally back in profit having held on through thick and thin since 2017. So tempting to get out now but I'm going to hang in here. Please let this not be another "false dawn", but the start of a sustained rise in the SP. Good luck all.
New Managing Director announced - no mention of the outgoing MD with the customary "thanks for his invaluable contribution etc etc" which seems a bit strange. Setting up a Scientific Advisory Board and Investment council looks long overdue. They appear to have some pretty impressive names on the SAB:
Ruth Atherton, PhD, JD, executive sponsor of the Bill & Melinda Gates Foundation Global Access Team, leading development and implementation of the foundation’s intellectual property strategy;
Andreas Busch, PhD, former Head of Research & Development and Chief Scientific Officer at Shire Pharmaceuticals;
Professor Trevor Jones, CBE, FMedSci, current Arix Non-Executive Director, former Group R&D director at The Wellcome Foundation Limited; and
Professor KJ Patel, FRS, FMedSci, Director of the MRC Weatherall Institute of Molecular Medicine and MRC Molecular Haematology Unit in Oxford.
My gut feel is that Arix share price could be due a decent run up to 100p++ if we get some positive news flow from their investment portfolio. I'd like to buy some more but the spread is still putting me off.
Thanks for posting this SGD27. I listened this morning and it was an impressive pitch by the Arix MD Jonathan Tobin. Harpoon and Autolus both sound like they have breakthrough potential in cancer treatments and should make good news flow to drive the share price. Considering adding some more, but the 91/97 spread today has put me off.
Thanks RightOn and JTS for the comments and it’s refreshing that this CAML board is populated by sane long term holders and so far free from hysterical rampers/derampers. Ive also been repositioning my SIPP portfolio over the last 2 years to a more defensive position and currently have 50% in cash or gold. CAML is my worst performing stock but I’ll sit and wait in hope of a slow but sustained recovery. Resumption of dividends would be a welcome bonus, but I don’t expect we will see this for a while.
I just talked myself into a top-up purchase today to bring my average buy price down. Good luck to all who hold..
I bought a small tranche in July 2019 and still holding patiently. Hoping that Arix will pull out of the slump in share price at some stage, and encouraged by the comments in the recent Hardman & Co analyst review:
https://www.hardmanandco.com/wp-content/uploads/2020/05/ARIX-1Q-Portfolio-update-19-May-2020.pdf
ARIX offers investors an opportunity to gain exposure to high-growth potential, early-stage biotechnology companies through a basket of 17 company investments, six of which are listed. Compared with direct single-stock investments, ARIX offers
investors a more balanced risk-reward profile.
At the close of business on 15 May 2020, the NAV was £206.9m, or 153p per share based on its current investment portfolio, which comprises:
? Core portfolio: Consisting of 11 companies with a total book value of £159m (77% of NAV), of which the six listed companies represent £117m.
? Discovery portfolio: Consisting of five companies with total book value of £18.1m (3.8% of NAV).
? Other interests: Totalling just £3.3m (1.4% of NAV).
? Cash: Gross cash of ca.£40.0m, of which ca.£2.0m is ring-fenced for existing portfolio company investments.
Given that the current market capitalisation of ARIX is just £110.5m (15 May 2020), the market appears to be valuing ARIX stock on the basis of cash (£40m) and only 40% (£70.5m) of the book value of ARIX’s core portfolio companies. Given that
there is increasingly positive momentum behind life sciences companies in the COVID-19 environment, the current 47% discount to NAV should be viewed as an opportunity, especially given the news flow expected to be announced by portfolio
companies in the coming months.
I share your pain as I also bought CAML in 2018 and with an average buy price of 230p it's been a really poor investment for me too. It looked then to be a relatively low risk, low cost, profitable copper producer with an experienced management team. And decent dividends too. I'll just sit tight and wait in hope for a sustained recovery in the share price. I bought an ETF in gold at the same time and wish I had put my CAML investment into that too...up 40% on gold, down 40% on CAML.
I sold my remaining 25% BRH shares at 34.525p yesterday, having sold 75% last week at 23.6p
Yes - too early I know - but that was before the great "pump and dump" exercise over the last few days.
Happy to bank profits from a share I held for 2 years as I'm building a defensive portfolio position based on cash and gold. BRH is a well managed and well positioned tech incubator business with some promising investments, but I don't buy the Covid19 hype which some are attaching to it at the moment. Over and out. Good luck to all LTH.
Lots of bullish talk here. I first bought into MTR in 2017 and still waiting patiently. Have averaged down on the dips but still need to reach 2p to break even. But the share price always seems to hit a brick wall at 1.5 and can't break through that barrier. Agree that we are in a much stronger position now than in 2017 when A4 / T3 etc were in early exploration stage and before the SFR / MOD deal. 2p by Christmas ? Let's hope so.....
I's like to sell some of my holding to bank some profit, but the spread is not attractive - showing as 17 to sell 20 to buy this morning. Got a quote from Hargreaves Lansdown to sell at 17.6 but I think I'll wait a while to see what happens...
Looks like Gyrometric have just landed a decent order...
RNS from Remote Monitoring Systems released today:
GyroMetric secures order from a global leader in marine propulsion systems as it maintains production
GyroMetric is continuing to maintain its bespoke production facility while strictly observing all the current Covid-19 safety recommendations. GyroMetric is pleased to announce an order for 10 units from a global leader in developing, producing and marketing innovative system solutions for marine propulsion systems. The client is a market and technology leader in the development of highly flexible couplings, shaft systems and elastic mounts. The order comprises 10 units and whilst the revenue will not be material for RMS, the commencement of the commercial rollout of the GyroMetric product with a world-renowned client is a further milestone and testament to the quality of the GyroMetric offering.
The recently appointed GyroMetric Systems CEO John Richardson, said "This order represents one of our major customers planning for growth in new markets, we are of course pleased to be able to maintain production to satisfy demand."
The Company and the management teams of both businesses continue to carefully marshal the limited cash resources available at present and particularly so in anticipation of the potential for broader impacts of Covid-19 on the economy in general including in markets in which the Company operates.
Trevor Brown, Executive Director of RMS, commented, "The Board of RMS has been pleased with the trajectory of its most recent investment, Cloudveil, however the recent significant upsurge in demand was unanticipated. It is too early to say clearly what the financial impact will be upon the Group's prospects but, combined with the new order for GyroMetric products, the future looks brighter than it was the last we communicated with our shareholders."
Hi all I bought today on the basis that this is a high growth and well managed company with decent cash reserves to get through the current crisis. Managed to buy at 555p via Hargreaves Lansdown despite the hideous spread. Plan to hold for 12 months minimum so good luck all.